S-Evans Biosciences, a stem cell specialist based in Hangzhou, has obtained tacit clinical trial approval from the National Medical Products Administration (NMPA) for its “human umbilical cord mesenchymal stem cell injection” in the treatment of moderate to severe acute respiratory distress syndrome (ARDS).
Product Development and ARDS Overview
The in-house developed product by S-Evans Biosciences features the active ingredient, human umbilical cord mesenchymal stem cells. These cells are isolated, screened, and expanded from healthy neonatal umbilical cord tissue in vitro. ARDS is a clinical syndrome characterized by diffuse inflammatory alveolar and pulmonary capillary injury, leading to rapid onset of hypoxemia and is one of the most common clinical syndromes in critically ill patients.
Potential Benefits of Mesenchymal Stem Cell Therapy for ARDS
Mesenchymal stem cell therapy for ARDS has been found to be safe and well tolerated, offering significant benefits to patients. It can improve lung function through immune regulation, regulation of endothelial and epithelial cell permeability, improvement of alveolar fluid clearance rate, and promotion of lung tissue repair. Additionally, it can delay the later stage of fibrosis in ARDS, providing a potentially life-saving treatment option for patients suffering from this critical condition.-Fineline Info & Tech
